Terlipressin has stood the test of time: Clinical overview in 2020 and future perspectives.
acute-on-chronic liver failure
ascites
cirrhosis
hepatorenal syndrome
terlipressin
variceal bleed
vasoconstrictor
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
18
08
2020
revised:
08
10
2020
accepted:
10
10
2020
pubmed:
17
10
2020
medline:
22
6
2021
entrez:
16
10
2020
Statut:
ppublish
Résumé
Vasoactive drugs form the mainstay of therapy for two of the most important complications of liver disease: hepatorenal syndrome (HRS) and acute variceal bleed (AVB). With cumulative evidence supporting the use in cirrhosis, terlipressin has been recommended for the management of HRS and AVB. However, owing to the safety concerns, terlipressin was not approved by food and drug administration (FDA) until now. In this review, we discuss the pharmacology and the major practice-changing studies on the safety and efficacy of terlipressin in patients with cirrhosis particularly focusing on existing indications like AVB and HRS and reviewing new data on the expanding indications in liver disease. The references for this review were identified from PUBMED with MeSH terms such as "terlipressin," "hepatorenal syndrome," "varices, esophagal and gastric," "ascites" and "cirrhosis." Terlipressin, a synthetic analogue of vasopressin, was introduced in 1975 to overcome the adverse effects of vasopressin. Terlipressin is an effective drug for HRS reversal in patients with liver cirrhosis and acute-on-chronic liver failure. There is documented mortality benefit with terlipressin therapy in HRS and AVB. Adverse effects are common with terlipressin and need to be monitored strictly. There is some evidence to support the use of this drug in refractory ascites, hepatic hydrothorax, paracentesis-induced circulatory dysfunction and perioperatively during liver transplantation. However, terlipressin is not yet recommended for such indications. In conclusion, terlipressin has stood the test of time with expanding indications and clear prerequisites for clinical use. Our review warrants a fresh perspective on the efficacy and safety of terlipressin.
Substances chimiques
Vasoconstrictor Agents
0
Lypressin
50-57-7
Terlipressin
7Z5X49W53P
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2888-2905Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Sarin SK, Sharma P. Terlipressin: an asset for hepatologists!. Hepatology. 2011;54(2):724-728.
Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology. 2002;122(4):923-930.
Cavallin M, Kamath PS, Merli M, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomised trial. Hepatology. 2015;62(2):567-574.
Boyer TD, Sanyal AJ, Wong F, et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology. 2016;150(7):1579-89.e2.
Sanyal AJ, Boyer TD, Frederick RT, et al. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies. Aliment Pharmacol Ther. 2017;45(11):1390-1402.
Wong FCM, Reddy KR, Rubin RA, et al. The CONFIRM study: a North American randomised controlled trial (RCT) of terlipressin plus albumin for the treatment of hepatorenal syndrome type 1 (HRS-1). Hepatology. 2019;70:1480-1481.
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460.
Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65(1):310-335.
Møller S, Hansen EF, Becker U, Brinch K, Henriksen JH, Bendtsen F. Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients. Liver. 2000;20(1):51-59.
Krag A, Møller S, Henriksen JH, Holstein-Rathlou NH, Larsen FS, Bendtsen F. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology. 2007;46(6):1863-1871.
Prowse CV, Douglas JG, Forrest JA, Forsling ML. Haemostatic effects of lysine vasopressin and triglycyl lysine vasopressin infusion in patients with cirrhosis. Eur J Clin Invest. 1980;10(1):49-54.
Pesaturo AB, Jennings HR, Voils SA. Terlipressin: vasopressin analog and novel drug for septic shock. Ann Pharmacother. 2006;40(12):2170-2177.
Nilsson G, Lindblom P, Ohlin M, Berling R, Vernersson E. Pharmacokinetics of terlipressin after single i.v. doses to healthy volunteers. Drugs Exp Clin Res. 1990;16(6):307-314.
Turco L, Garcia-Tsao G. Portal hypertension: pathogenesis and diagnosis. Clin Liver Dis. 2019;23(4):573-587.
Martell M, Coll M, Ezkurdia N, Raurell I, Genescà J. Physiopathology of splanchnic vasodilation in portal hypertension. World J Hepatol. 2010;2(6):208-220.
Stadlbauer VP, Wright GAK, Banaji M, et al. Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis. Gastroenterology. 2008;134(1):111-119.
Mindikoglu AL, Dowling TC, Wong-You-Cheong JJ, et al. A pilot study to evaluate renal hemodynamics in cirrhosis by simultaneous glomerular filtration rate, renal plasma flow, renal resistive indices and biomarkers measurements. Am J Nephrol. 2014;39(6):543-552.
Angeli P, Garcia-Tsao G, Nadim MK, Parikh CR. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J Hepatol. 2019;71(4):811-822.
Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;62(4):968-974.
Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;8(5):1151-1157.
Ruiz-del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology. 2005;42(2):439-447.
Moreau R, Lebrec D. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. Hepatology. 2006;43(3):385-394.
Maiwall R, Pasupuleti SSR, Bihari C, et al. Incidence, risk factors, and outcomes of transition of acute kidney injury to chronic kidney disease in cirrhosis: a prospective cohort study. Hepatology. 2020;71(3):1009-1022.
Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomised, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008;134(5):1360-1368.
Uriz J, Ginès P, Cárdenas A, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol. 2000;33(1):43-48.
Nguyen-Tat M, Jäger J, Rey JW, et al. Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2. United European Gastroenterol J. 2019;7(4):529-537.
Alessandria C, Ottobrelli A, Debernardi-Venon W, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomised, unblinded, pilot study. J Hepatol. 2007;47(4):499-505.
Neri S, Pulvirenti D, Malaguarnera M, et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci. 2008;53(3):830-835.
Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomised placebo-controlled clinical trial. J Gastroenterol Hepatol. 2003;18(2):152-156.
Martín-Llahí M, Pépin MN, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomised study. Gastroenterology. 2008;134(5):1352-1359.
Sharma P, Kumar A, Shrama BC, Sarin SK. An open label, pilot, randomised controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol. 2008;103(7):1689-1697.
Singh V, Ghosh S, Singh B, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomised study. J Hepatol. 2012;56(6):1293-1298.
Ghosh S, Choudhary NS, Sharma AK, et al. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomised pilot study. Liver Int. 2013;33(8):1187-1193.
Saif RU, Dar HA, Sofi SM, Andrabi MS, Javid G, Zargar SA. Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: a randomised controlled study. Indian J Gastroenterol. 2018;37(5):424-429.
Angeli P, Gines P. Hepatorenal syndrome, MELD score and liver transplantation: an evolving issue with relevant implications for clinical practice. J Hepatol. 2012;57(5):1135-1140.
Piano S, Gambino C, Vettore E, et al. Response to terlipressin and albumin is associated with improved liver transplant outcomes in patients with hepatorenal syndrome. Hepatology. 2020. https://doi.org/10.1002/hep.31529 [published online ahead of print].
Sharma P, Moore K, Ganger D, Grewal P, Brown RS Jr. Role of terlipressin and albumin for hepatorenal syndrome in liver transplantation. Liver Transpl. 2020;26(10):1328-1336.
Moore K, Jamil K, Verleger K, et al. Real-world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome. Aliment Pharmacol Ther. 2020;52(2):351-358.
Sridharan K, Sivaramakrishnan G. Vasoactive agents for hepatorenal syndrome: a mixed treatment comparison network meta-analysis and trial sequential analysis of randomized clinical trials. J Gen Intern Med. 2018;33(1):97-102.
Facciorusso A, Chandar AK, Murad MH, et al. Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2017;2(2):94-102.
Wang H, Liu A, Bo W, Feng X, Hu Y. Terlipressin in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. Medicine. 2018;97(16):e0431.
Best LM, Freeman SC, Sutton AJ, et al. Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis. Cochrane Database Syst Rev. 2019;9(9):Cd013103.
Kulkarni AV, Kumar P, Sharma M, et al. Pathophysiology and prevention of paracentesis-induced circulatory dysfunction: a concise review. J Clin Transl Hepatol. 2020;8(1):42-48.
Gerbes AL, Huber E, Gülberg V. Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.v. bolus administration. Gastroenterology. 2009;137(3):1179; author reply -81.
Cavallin M, Piano S, Romano A, et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomised controlled study. Hepatology. 2016;63(3):983-992.
Escorsell A, Bandi JC, Moitinho E, et al. Time profile of the haemodynamic effects of terlipressin in portal hypertension. J Hepatol. 1997;26(3):621-627.
Goyal O, Sidhu SS, Sehgal N, Puri S. Noradrenaline is as effective as terlipressin in hepatorenal syndrome type 1: a prospective randomised trial. J Assoc Physicians India. 2016;64(9):30-35.
Ortega R, Ginès P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomised study. Hepatology. 2002;36(4 Pt 1):941-948.
Nazar A, Pereira GH, Guevara M, et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2010;51(1):219-226.
Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology. 2008;48(6):2064-2077.
Jiang QQ, Han MF, Ma K, et al. Acute kidney injury in acute-on-chronic liver failure is different from in decompensated cirrhosis. World J Gastroenterol. 2018;24(21):2300-2310.
Fickert P, Krones E, Pollheimer MJ, et al. Bile acids trigger cholemic nephropathy in common bile-duct-ligated mice. Hepatology. 2013;58(6):2056-2069.
Davenport A, Sheikh MF, Lamb E, Agarwal B, Jalan R. Acute kidney injury in acute-on-chronic liver failure: where does hepatorenal syndrome fit? Kidney Int. 2017;92(5):1058-1070.
Rodríguez E, Elia C, Solà E, et al. Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis. J Hepatol. 2014;60(5):955-961.
Piano S, Schmidt HH, Ariza X, et al. Association between grade of acute on chronic liver failure and response to terlipressin and albumin in patients with hepatorenal syndrome. Clin Gastroenterol Hepatol. 2018;16(11):1792-800.e3.
Arora V, Maiwall R, Rajan V, et al. Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure. Hepatology. 2020;71(2):600-610.
Saner FH, Canbay A, Gerken G, Broelsch CE. Pharmacology, clinical efficacy and safety of terlipressin in esophageal varices bleeding, septic shock and hepatorenal syndrome. Expert Rev Gastroenterol Hepatol. 2007;1(2):207-217.
Freeman JG, Cobden I, Lishman AH, Record CO. Controlled trial of terlipressin ('Glypressin') versus vasopressin in the early treatment of oesophageal varices. Lancet. 1982;2(8289):66-68.
Freeman JG, Cobden I, Record CO. Placebo-controlled trial of terlipressin (glypressin) in the management of acute variceal bleeding. J Clin Gastroenterol. 1989;11(1):58-60.
Walker S, Stiehl A, Raedsch R, Kommerell B. Terlipressin in bleeding esophageal varices: a placebo-controlled, double-blind study. Hepatology. 1986;6(1):112-115.
Walker S, Kreichgauer HP, Bode JC. Terlipressin vs. somatostatin in bleeding esophageal varices: a controlled, double-blind study. Hepatology. 1992;15(6):1023-1030.
Feu F, Ruiz del Arbol L, Bañares R, Planas R, Bosch J. Double-blind randomised controlled trial comparing terlipressin and somatostatin for acute variceal hemorrhage. Variceal Bleeding Study Group. Gastroenterology. 1996;111(5):1291-1299.
Abid S, Jafri W, Hamid S, et al. Terlipressin vs. octreotide in bleeding esophageal varices as an adjuvant therapy with endoscopic band ligation: a randomised double-blind placebo-controlled trial. Am J Gastroenterol. 2009;104(3):617-623.
Seo YS, Park SY, Kim MY, et al. Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage. Hepatology. 2014;60(3):954-963.
Ioannou G, Doust J, Rockey DC. Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database Syst Rev. 2003;(1):Cd002147.
Sridharan K, Sivaramakrishnan G. Vasoactive agents for the management of variceal bleeding: a mixed treatment comparison network meta-analysis and trial sequential analysis of randomized clinical trials. Drug Res (Stuttg). 2019;69(9):487-495.
de Franchis R. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualising care for portal hypertension. J Hepatol. 2015;63(3):743-752.
Jha SK, Mishra M, Jha A, Dayal VM. Comparison of continuous versus intermittent infusions of terlipressin for the control of acute variceal bleeding in patients with portal hypertension: an open-label randomised controlled trial. Indian J Gastroenterol. 2018;37(4):313-320.
Moreau R, Barrière E, Tazi KA, et al. Terlipressin inhibits in vivo aortic iNOS expression induced by lipopolysaccharide in rats with biliary cirrhosis. Hepatology. 2002;36(5):1070-1078.
Choudhury A, Kedarisetty CK, Vashishtha C, et al. A randomised trial comparing terlipressin and noradrenaline in patients with cirrhosis and septic shock. Liver Int. 2017;37(4):552-561.
Fimiani B, Guardia DD, Puoti C, et al. The use of terlipressin in cirrhotic patients with refractory ascites and normal renal function: a multicentric study. Eur J Intern Med. 2011;22(6):587-590.
Gow PJ, Ardalan ZS, Vasudevan A, Testro AG, Ye B, Angus PW. Outpatient terlipressin infusion for the treatment of refractory ascites. Am J Gastroenterol. 2016;111(7):1041-1042.
Xing F, Li S, Zhang JJ, et al. Observation of the therapeutic and characteristic effects of terlipressin on refractory cirrhotic ascites. Zhonghua Gan Zang Bing Za Zhi. 2019;27(12):982-988.
Ibrisim D, Cakaloglu Y, Akyuz F, et al. Treatment of hepatic hydrothorax with terlipressin in a cirrhotic patient. Scand J Gastroenterol. 2006;41(7):862-865.
Kulkarni AV, Sharma M, Kumar P, Gupta R, Rao PN. Midodrine for hepatic hydrothorax. Hepatology. 2020. https://doi.org/10.1002/hep.31513 [published online ahead of print].
Moreau R, Asselah T, Condat B, et al. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study. Gut. 2002;50(1):90-94.
Singh V, Kumar R, Nain CK, Singh B, Sharma AK. Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomised study. J Gastroenterol Hepatol. 2006;21(1 Pt 2):303-307.
Kulkarni AV, Kumar P, Singh S, et al. Prevention of paracentesis-induced circulatory dysfunction-a systematic review and network meta-analysis. GastroHep. 2020;2(3):92-101.
Mukhtar A, Salah M, Aboulfetouh F, et al. The use of terlipressin during living donor liver transplantation: effects on systemic and splanchnic hemodynamics and renal function. Crit Care Med. 2011;39(6):1329-1334.
Ibrahim N, Hasanin A, Allah SA, et al. The haemodynamic effects of the perioperative terlipressin infusion in living donor liver transplantation: a randomised controlled study. Indian J Anaesth. 2015;59(3):156-164.
Fayed N, Refaat EK, Yassein TE, Alwaraqy M. Effect of perioperative terlipressin infusion on systemic, hepatic, and renal hemodynamics during living donor liver transplantation. J Crit Care. 2013;28(5):775-782.
Kandil MA, Abouelenain KM, Alsebaey A, et al. Impact of terlipressin infusion during and after live donor liver transplantation on incidence of acute kidney injury and neutrophil gelatinase-associated lipocalin serum levels: a randomised controlled trial. Clin Transplant. 2017;31(8):e13019.
Mukhtar A, Mahmoud I, Obayah G, et al. Intraoperative terlipressin therapy reduces the incidence of postoperative acute kidney injury after living donor liver transplantation. J Cardiothorac Vasc Anesth. 2015;29(3):678-683.
Reddy MS, Kaliamoorthy I, Rajakumar A, et al. Double-blind randomised controlled trial of the routine perioperative use of terlipressin in adult living donor liver transplantation. Liver Transpl. 2017;23(8):1007-1014.
Asakura T, Ohkohchi N, Orii T, et al. Portal vein pressure is the key for successful liver transplantation of an extremely small graft in the pig model. Transpl Int. 2003;16(6):376-382.
Fahrner R, Patsenker E, de Gottardi A, et al. Elevated liver regeneration in response to pharmacological reduction of elevated portal venous pressure by terlipressin after partial hepatectomy. Transplantation. 2014;97(9):892-900.
Mahdy MM, Abbas MS, Kamel EZ, et al. Effects of terlipressin infusion during hepatobiliary surgery on systemic and splanchnic haemodynamics, renal function and blood loss: a double-blind, randomised clinical trial. BMC Anesthesiol. 2019;19(1):106.
Abbas MS, Mohamed KS, Ibraheim OA, et al. Effects of terlipressin infusion on blood loss and transfusion needs during liver resection: a randomised trial. Acta Anaesthesiol Scand. 2019;63(1):34-39.
Eefsen M, Dethloff T, Frederiksen HJ, Hauerberg J, Hansen BA, Larsen FS. Comparison of terlipressin and noradrenalin on cerebral perfusion, intracranial pressure and cerebral extracellular concentrations of lactate and pyruvate in patients with acute liver failure in need of inotropic support. J Hepatol. 2007;47(3):381-386.
Wendon J, Cordoba J, Dhawan A, et al. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017;66(5):1047-1081.
Shawcross DL, Davies NA, Mookerjee RP, et al. Worsening of cerebral hyperemia by the administration of terlipressin in acute liver failure with severe encephalopathy. Hepatology. 2004;39(2):471-475.
Lee WM, Stravitz RT, Larson AM. Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. Hepatology. 2012;55(3):965-967.
Price LC, Forrest P, Sodhi V, et al. Use of vasopressin after Caesarean section in idiopathic pulmonary arterial hypertension. Br J Anaesth. 2007;99(4):552-555.
Kalambokis G, Korantzopoulos P, Nikas SA, Theodorou A, Tsianos EV. Significant improvement of portopulmonary hypertension after 1-week terlipressin treatment. J Hepatol. 2008;48(4):678-680.
Altintas E, Akkus N, Gen R, Helvaci MR, Sezgin O, Oguz D. Effects of terlipressin on systolic pulmonary artery pressure of patients with liver cirrhosis: an echocardiographic assessment. World J Gastroenterol. 2004;10(15):2278-2280.
Kulkarni AV, Kumar P, Rao NP, Reddy N. Terlipressin-induced ischaemic skin necrosis. BMJ Case Rep. 2020;13(1):e233089.
Sen S, Mookerjee RP, Jalan R. Terlipressin-induced vasoconstriction reversed with N-acetylcysteine: a case for combined use in hepatorenal syndrome? Gastroenterology. 2002;123(6):2160-2161.
Krag A, Bendtsen F, Mortensen C, Henriksen JH, Møller S. Effects of a single terlipressin administration on cardiac function and perfusion in cirrhosis. Eur J Gastroenterol Hepatol. 2010;22(9):1085-1092.
Israelsen M, Dahl EK, Madsen BS, et al. Dobutamine reverses the cardio-suppressive effects of terlipressin without improving renal function in cirrhosis and ascites: a randomised controlled trial. Am J Physiol Gastrointest Liver Physiol. 2020;318(2):G313-G321.
Solà E, Lens S, Guevara M, et al. Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension. Hepatology. 2010;52(5):1783-1790.
Pan X, Zhou Z, Jin X, Shi D. Clinical characteristics and risk factors of severe hyponatremia in cirrhotic patients treated with terlipressin. J Clin Pharm Ther. 2020;45(1):191-198.
Sharma P, Singh S, Sarin SK. Hyponatremia in patients with acute variceal bleeding treated with terlipressin. Hepatology. 2011;53(2):714; author reply -5.
Abdel-Razik A, Mousa N, Abdelsalam M, et al. Endothelin-1/nitric oxide ratio as a predictive factor of response to therapy with terlipressin and albumin in patients with type-1 hepatorenal syndrome. Front Pharmacol. 2020;11:9.
Belcher JM, Sanyal AJ, Peixoto AJ, et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology. 2014;60(2):622-632.
Simonetto DA, Gines P, Kamath PS. Hepatorenal syndrome: pathophysiology, diagnosis, and management. BMJ. 2020;370:m2687.
Anand A, Shalimar. Is terlipressin superior to noradrenaline in the treatment of acute kidney injury in acute-on-chronic liver failure? Hepatology. 2019;69(1):463-464.
van Vugt JL, Levolger S, de Bruin RW, van Rosmalen J, Metselaar HJ, IJzermans JN. Systematic review and meta-analysis of the impact of computed tomography-assessed skeletal muscle mass on outcome in patients awaiting or undergoing liver transplantation. Am J Transplant. 2016;16(8):2277-2292.
Chapman B, Gow P, Sinclair M, et al. Continuous terlipressin infusion is associated with improved diet intake and muscle strength in patients awaiting liver transplant. JHEP Rep. 2019;1(2):107-113.